Prescription medicine
Propranolol Brand names: Inderal, Innopran, Hemangeol
Propranolol (Inderal) is a prescription medicine with an FDA approval on record since 1967. FDA's NDC Directory lists it from 42 generic labelers, and pharmacies paid $0.0493 per propranolol 20 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- In shortage
Check it at the source: the propranolol FDA label on DailyMed (effective January 15, 2026, Mylan Pharmaceuticals Inc.); the NDA 16418 record on Drugs@FDA; every propranolol label on DailyMed.
Highlights of the record
FDA label of January 15, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageHypertension Propranolol hydrochloride tablets are indicated in the management of hypertension.
Forms and strengths
- 10 mg
- 20 mg
- 40 mg
- 60 mg
- 80 mg
- 120 mg
- 160 mg
- 1 mg/ml
- 4.28 mg/ml
- 20 mg/5ml
- 40 mg/5ml
Tablet; extended-release capsule; solution; injection (solution); injection.
On the market
- Earliest approval on file
- November 13, 1967 Inderal, Wyeth Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 77 first July 30, 1985; 24 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 45 of which 42 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- October 16, 2028 Hemangeol oral solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.0493 per tablet Propranolol 20 mg tablet
- Shortage (FDA)
- 1 of 2 presentations limited or unavailable updated September 18, 2026
- Recalls by its makers (FDA)
- 4 since 2012 0 Class I among all firms' recalls; latest January 26, 2022; 8 more by firms not listed as its makers
- FAERS reports
- 71,660 through July 30, 2026
What is propranolol used for?
From the label: indications and usageHypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. […]
Conditions named in the indications of propranolol's FDA labels, with every medicine labeled for each:
From other propranolol labelsHigh blood pressure: INDICATIONS AND USAGE Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension.
Migraine: Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache.
FDA pharmacologic class: beta-Adrenergic Blocker.
Source: FDA drug label (Propranolol Hydrochloride), Mylan Pharmaceuticals Inc., effective January 15, 2026 (SPL set b94dcec7-7633-4a33-9cea-48161adeaf93), via openFDA; the full label on DailyMed
What does the patient leaflet for propranolol say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about HEMANGEOL?HEMANGEOL can cause serious side effects, including: Low blood sugar (hypoglycemia), especially if your child is not taking feedings, or is vomiting. HEMANGEOL may make it more difficult to recognize the signs and symptoms of low blood sugar in your child. To help reduce the risk of low blood sugar with HEMANGEOL: Give HEMANGEOL during or shortly after feeding your child. Feed your child regularly during treatment. Tell your doctor if your child has a poor appetite. If your child is not taking feedings, for example, due to an illness or vomiting, do not give HEMANGEOL until your child is taking feedings normally again. If your child has any of the signs or symptoms of low blood sugar listed below during treatment with HEMANGEOL, stop giving your child HEMANGEOL, call your healthcare provider immediately or go to the emergency room. If the child is conscious, give him/her a drink of liquid containing sugar. Signs or symptoms of low blood sugar include: pale, blue or purple skin color, sweating, irritability, crying for no apparent reason, irregular or fast heartbeat, poor feeding, low body temperature, unusual sleepiness, seizures, breathing stops for short periods of time, and loss of consciousness.
From the patient leaflet: How should I store HEMANGEOL?Store HEMANGEOL at room temperature between 68 o F to 77 o F (20 o C to 25 o C). Do not freeze. Do not shake before use. Safely throw away any opened bottle of HEMANGEOL after 2 months, even if there is medicine left in the bottle. Keep HEMANGEOL and all medicines out of the reach of children.
Source: FDA drug label (HEMANGEOL), Pierre Fabre Pharmaceuticals, Inc., effective June 25, 2026 (SPL set b6f9dd2a-632b-87eb-70f0-b2064d7ed48a), via openFDA; the full label on DailyMed
Is there a generic for propranolol (Inderal)?
The FDA approved the first generic propranolol on July 30, 1985. 77 generic applications are approved; 24 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists propranolol from 42 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Inderal LA capsules; a patent listed only for Hemangeol oral solution runs to October 16, 2028. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1967 earliest approval on file
- 1985 first generic approved
- 2028 last listed patent
- 2023 to now in shortage
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for propranolol (Inderal)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0493 per Propranolol 20 mg tablet, down 17% from $0.0594 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Propranolol 20 mg tablet (generic)
- Inderal xl 80 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Propranolol 10 mg tablet | Generic | $0.0466 per tablet | $1.40 | -13% |
| Propranolol 20 mg tablet | Generic | $0.0493 per tablet | $1.48 | -17% |
| Propranolol 20 mg/5 mL solution | Generic | $0.0922 per mL | n/a | -2% |
| Propranolol 40 mg tablet | Generic | $0.0766 per tablet | $2.30 | -4% |
| Propranolol 40 mg/5 mL solution | Generic | $0.133 per mL | n/a | n/a |
| Propranolol 60 mg tablet | Generic | $0.159 per tablet | $4.76 | +8% |
| Propranolol 80 mg tablet | Generic | $0.159 per tablet | $4.77 | +5% |
| Propranolol ER 120 mg capsule | Generic | $0.196 per capsule | $5.87 | -6% |
| Propranolol ER 160 mg capsule | Generic | $0.305 per capsule | $9.15 | -1% |
| Propranolol ER 60 mg capsule | Generic | $0.170 per capsule | $5.10 | -5% |
| Propranolol ER 80 mg capsule | Generic | $0.191 per capsule | $5.72 | -3% |
| Inderal xl 80 mg capsule | Brand | $68.70 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $2,061.11 | -1% |
| Innopran xl 80 mg capsule | Brand | $68.70 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $2,061.11 | -1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is propranolol in shortage?
The FDA Drug Shortage Database lists 1 of 2 propranolol presentations as limited or unavailable (updated September 18, 2026); the first entry was posted on October 31, 2023. 1 more presentation is on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10) | Hikma Pharmaceuticals USA, Inc. | Current | September 18, 2026 |
| Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01) | Fresenius Kabi USA, LLC | Current | September 15, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has propranolol been recalled?
The FDA's Enforcement Report lists 12 recalls naming propranolol since 2012: 0 Class I (the most serious), 12 Class II, 0 Class III; 0 still ongoing. 8 of them are by firms that FDA's NDC Directory does not list as a maker of propranolol and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| January 26, 2022 | Class II | CARDINAL HEALTHCARE | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. |
| August 13, 2014 | Class II | Fresenius Kabi USA, LLC | CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used … |
| July 9, 2014 | Class II | Gyma Laboratories Of Amer,Inc not a listed maker | cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert … |
| August 6, 2013 | Class II | Teva Pharmaceuticals USA, Inc. | Failed Tablet/Capsule Specification: Teva is recalling certain lots of Propanolol HCl Tablets, 10 mg due to the potential of some tablets not conforming to … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; PROPRANOLOL HCL, Tablet, 10 mg may be potentially mislabeled as PIOGLITAZONE HCL, Tablet, 15 mg, NDC 00093204856, Pedigree: AD52778_70 … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; PROPRANOLOL HCL, Tablet, 10 mg may be potentially mislabeled as PERPHENAZINE, Tablet, 16 mg, NDC 00781104901, Pedigree: AD21790_31, EXP … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; PROPRANOLOL HCL Tablet, 5 mg (1/2 of 10 mg) may be potentially mislabeled as LITHIUM CARBONATE ER, Tablet, 225 mg (1/2 of 450 mg), NDC … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; PROPRANOLOL HCL Tablet, 10 mg may be potentially mislabeled as LACTOBACILLUS ACIDOPHILUS, Capsule, NDC 54629011101, Pedigree: AD65311_4 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the propranolol label say about other medicines?
The propranolol label names 55 other medicines in its interaction, contraindication or warning sections. The labels of 45 other medicines name propranolol. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Alprazolam | drug interactions | The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. |
| Amiodarone | drug interactions | Substrates or Inhibitors of CYP2D6 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Bupropion | drug interactions | Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when … |
| Chlorpromazine | drug interactions | Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level. |
| Cholestyramine | drug interactions | Lipid Lowering Drugs Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations. |
| Cimetidine | drug interactions | Substrates or Inhibitors of CYP2D6 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Ciprofloxacin | drug interactions | Substrates or Inhibitors of CYP1A2 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Clonidine | drug interactions | The antihypertensive effects of clonidine may be antagonized by beta-blockers. |
| Colestipol | drug interactions | Lipid Lowering Drugs Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations. |
| Diazepam | drug interactions | Benzodiazepines Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. |
| Digoxin | warnings and precautions | The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. |
| Diltiazem | drug interactions | Co-administration of propranolol and diltiazem in patients with cardiac disease has been associated with bradycardia, hypotension, high-degree heart block, and heart failure. |
| Dobutamine | drug interactions | Isoproterenol and Dobutamine Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. |
| Doxazosin | drug interactions | Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin. |
Every other medicine the propranolol label names
| Medicine named | Section | What the label says |
|---|---|---|
| Epinephrine | drug interactions | Inotropic Agents Patients on long-term therapy with propranolol may experience uncontrolled hypertension if administered epinephrine as a consequence of unopposed alpha-receptor stimulation. |
| Fluconazole | drug interactions | … co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, tenioposide, and tolbutamide. |
| Fluoxetine | drug interactions | … or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Fluvastatin | drug interactions | Propranolol did not have an effect on the pharmacokinetics of fluvastatin. |
| Fluvoxamine | drug interactions | … inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Glucagon | warnings and precautions | In these patients, consider other medications (e.g., intravenous fluids, glucagon). |
| Haloperidol | drug interactions | Neuroleptic Drugs Hypotension and cardiac arrest have been reported with the concomitant use of propranolol and haloperidol. |
| Imipramine | drug interactions | … co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Indomethacin | drug interactions | Administration of indomethacin with propranolol may reduce the efficacy of propranolol in reducing blood pressure and heart rate. |
| Isoniazid | drug interactions | … CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Isoproterenol | drug interactions | Isoproterenol and Dobutamine Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. |
| Lansoprazole | drug interactions | No interactions were observed with either ranitidine or lansoprazole. |
| Lidocaine | drug interactions | The metabolism of lidocaine is inhibited by co-administration of propranolol, resulting in a 25% increase in lidocaine concentrations. |
| Lorazepam | drug interactions | The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. |
| Lovastatin | drug interactions | Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. |
| Metoclopramide | drug interactions | Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics. |
| Montelukast | drug interactions | CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy … |
| Nicardipine | drug interactions | Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co-administration of nisoldipine and by 80% and 47%, by co-administration of nicardipine. |
| Nifedipine | drug interactions | The mean C max and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol. |
| Nisoldipine | drug interactions | Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co-administration of nisoldipine and by 80% and 47%, by co-administration of nicardipine. |
| Omeprazole | drug interactions | No interaction was observed with omeprazole. |
| Oxazepam | drug interactions | The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. |
| Paroxetine | drug interactions | … of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Phenobarbital | drug interactions | Inducers of Hepatic Drug Metabolism Blood levels of propranolol may be decreased by co-administration with inducers such as rifampin, ethanol, phenytoin, and phenobarbital. |
| Phenytoin | drug interactions | Inducers of Hepatic Drug Metabolism Blood levels of propranolol may be decreased by co-administration with inducers such as rifampin, ethanol, phenytoin, and phenobarbital. |
| Pravastatin | drug interactions | Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. |
| Prazosin | drug interactions | Alpha Blockers Prazosin has been associated with prolongation of first dose hypotension in the presence of beta-blockers. |
| Propafenone | drug interactions | Cardiovascular Drugs Antiarrhythmics The AUC of propafenone is increased by more than 200% by co-administration of propranolol. |
| Quinidine | drug interactions | … such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Ranitidine | drug interactions | No interactions were observed with either ranitidine or lansoprazole. |
| Rifampin | drug interactions | Inducers of Hepatic Drug Metabolism Blood levels of propranolol may be decreased by co-administration with inducers such as rifampin, ethanol, phenytoin, and phenobarbital. |
| Ritonavir | drug interactions | … amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. |
| Rizatriptan | drug interactions | … fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Terazosin | drug interactions | Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin. |
| Theophylline | drug interactions | … imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Thioridazine | drug interactions | Neuroleptic Drugs Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and … |
| Triazolam | drug interactions | The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. |
| Verapamil | drug interactions | There have been reports of significant bradycardia, heart failure, and cardiovascular collapse with concurrent use of verapamil and beta-blockers. |
| Warfarin | drug interactions | Warfarin Concomitant administration of propranolol and warfarin has been shown to increase warfarin bioavailability and increase prothrombin time. |
| Zileuton | drug interactions | … cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
| Zolmitriptan | drug interactions | … ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. |
Other labels that name propranolol
- Acetaminophen and oxycodone
- Armodafinil
- Aspirin, butalbital, caffeine and codeine
- Celecoxib
- Diclofenac
- Dihydroergotamine
- Disopyramide
- Dronedarone
- Ergotamine
- Fenoprofen
- Finasteride
- Histamine
- Ibuprofen
- Isradipine
- Ketorolac
- Lasmiditan
- Lisinopril
- Mefenamic acid
- Meloxicam
- Miglitol
- Modafinil
- Naproxen
- Nefazodone
- Nicotine
- Oxaprozin
- Piroxicam
Source: FDA drug label (Propranolol Hydrochloride), Mylan Pharmaceuticals Inc., effective January 15, 2026 (SPL set b94dcec7-7633-4a33-9cea-48161adeaf93), via openFDA; the full label on DailyMed
What do FAERS reports show for propranolol?
The FDA Adverse Event Reporting System holds 71,660 reports that list propranolol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 7,184 are coded as a death and 21,992 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as propranolol?
75 other medicines are given the same way (oral) and in the same FDA class as propranolol or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Metoprolol | High blood pressure, Angina | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Carvedilol | High blood pressure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Atenolol | High blood pressure, Angina | 35 labelers | $0.0217 per tablet 25 mg tablet | No current entry |
| Labetalol | High blood pressure | 31 labelers | $0.215 per tablet 300 mg tablet | No current entry |
| Nebivolol | High blood pressure | 23 labelers | $0.141 per tablet 10 mg tablet | A presentation being discontinued |
| Nadolol | High blood pressure, Angina | 16 labelers | $0.147 per tablet 20 mg tablet | No current entry |
| Bisoprolol | High blood pressure | 24 labelers | $0.114 per tablet 5 mg tablet | No current entry |
| Bisoprolol and hydrochlorothiazide | High blood pressure | 11 labelers | $0.209 per tablet 10-6.25 mg tablet | No current entry |
Every medicine labeled for the same conditions as propranolol
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does propranolol compare with medicines for the same use?
28 side-by-side pages set propranolol beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to propranolol
- 75 medicines for the same use
- Other beta blockers
- the pharmacologic class, with prices and generics
- Propranolol side effects
- the label's list beside FAERS reports
- Propranolol shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other